Leap Therapeutics Completes Promising Phase 2 Cancer Study

Leap Therapeutics ((LPTX)) announced an update on their ongoing clinical study.

Leap Therapeutics has recently completed a Phase 2 study titled ‘A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma.’ The study aimed to assess the efficacy and safety of DKN-01, alone or combined with Paclitaxel, in treating recurrent epithelial endometrial and ovarian cancers, as well as carcinosarcoma. This study is significant as it explores potential new treatment avenues for these challenging cancer types.

The interventions tested include DKN-01, a drug administered via IV infusion, both as a monotherapy and in combination with Paclitaxel, another IV-administered drug. The goal is to evaluate their effectiveness in controlling and reducing cancer progression.

The study employed a non-randomized, parallel intervention model with no masking, focusing primarily on treatment. This straightforward design was chosen to directly observe the treatment effects of DKN-01, alone and in combination, on the target cancers.

The study began on March 5, 2018, with primary completion in early 2023. The latest update was submitted on July 30, 2025, indicating ongoing data analysis and result dissemination. These timelines are crucial for investors tracking the development and potential market entry of new cancer therapies.

This update could positively impact Leap Therapeutics’ stock performance by enhancing investor confidence in the company’s research capabilities and potential market share in oncology. As the study results become available, they may influence competitive dynamics within the cancer treatment industry, particularly among companies focusing on similar cancer types.

The study is completed, with further details available on the ClinicalTrials portal.